Metropolitan Life Insurance CO Bei Gene, Ltd. Transaction History

Metropolitan Life Insurance CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $221,310 - $316,610	-1,000 Closed	0 $0
Q3 2020 Jun 26, 2023	BUY	$189.18 - $286.44 $340,524 - $515,592	1,800 New	1,800 $515,000
Q3 2020 Mar 30, 2023	SELL	$189.18 - $286.44 $37,836 - $57,288	-200 Reduced 10.0%	1,800 $515,000
Q2 2020 Jun 26, 2023	BUY	$123.9 - $195.41 $247,800 - $390,820	2,000 New	2,000 $376,000
Q2 2020 Mar 30, 2023	BUY	$123.9 - $195.41 $37,170 - $58,623	300 Added 17.65%	2,000 $376,000
Q1 2020 Jul 12, 2023	BUY	$121.84 - $173.19 $207,128 - $294,423	1,700 New	1,700 $209,000
Q4 2019 Jul 12, 2023	BUY	$115.78 - $208.34 $196,826 - $354,178	1,700 New	1,700 $281,000
Q3 2019 Jul 12, 2023	BUY	$120.61 - $148.29 $205,037 - $252,093	1,700 New	1,700 $208,000
Q3 2019 Mar 30, 2023	BUY	$120.61 - $148.29 $24,122 - $29,658	200 Added 13.33%	1,700 $208,000
Q2 2019 Jul 12, 2023	BUY	$113.99 - $146.86 $170,985 - $220,290	1,500 New	1,500 $185,000
Q1 2019 Jul 13, 2023	BUY	$122.82 - $151.83 $184,230 - $227,745	1,500 New	1,500 $198,000
Q1 2019 Mar 30, 2023	BUY	$122.82 - $151.83 $184,230 - $227,745	1,500 New	1,500 $198,000
Q1 2019 May 16, 2019	SELL	$122.82 - $151.83 $1.01 Million - $1.25 Million	-8,224 Reduced 89.16%	1,000 $132,000
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $1.01 Million - $1.25 Million	8,224 Added 822.4%	9,224 $310,000
Q4 2018 Jul 13, 2023	BUY	$107.01 - $175.15 $107,010 - $175,150	1,000 New	1,000 $140,000
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $107,010 - $175,150	1,000 New	1,000 $140,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.